Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

NCT ID: NCT03444870

Last Updated: 2024-01-30

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

1053 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-06-06

Study Completion Date

2023-02-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This randomized, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of gantenerumab versus placebo in participants with early (prodromal to mild) AD. All participants must show evidence of beta-amyloid pathology. Eligible participants will be randomized 1:1 to receive either subcutaneous (SC) injection of gantenerumab or placebo. The primary efficacy assessment will be performed at the end of the double blind period at week 116. Participants will then be offered to enter into an open-label extension (OLE). Participants not willing to go to the OLE will participate in a long term follow-up period for up to 50 weeks after the last gantenerumab dose.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Gantenerumab

Gantenerumab will be administered as SC injections with gradual uptitration.

Group Type EXPERIMENTAL

Gantenerumab

Intervention Type DRUG

Gantenerumab will be administered as per the schedule specified in the respective arm.

Placebo

Placebo will be administered as SC injections with gradual uptitration.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo will be administered as per the schedule specified in the respective arm.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Gantenerumab

Gantenerumab will be administered as per the schedule specified in the respective arm.

Intervention Type DRUG

Placebo

Placebo will be administered as per the schedule specified in the respective arm.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

RO4909832

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Meets National Institute on Aging/Alzheimer's Association (NIAAA) core clinical criteria for probable AD dementia or prodromal AD (consistent with the NIAAA diagnostic criteria and guidelines for mild cognitive impairment)
* Evidence of the AD pathological process, as confirmed by CSF tau/A-beta42or amyloid PET scan
* Demonstrated abnormal memory function
* MMSE score greater than or equal to 22 (≥ 22)
* Clinical dementia rating-global score (CDR-GS) of 0.5 or 1.0
* Availability of a reliable study partner who accepts to participate in study procedures throughout the 2 years duration of study
* If receiving symptomatic AD medications, the dosing regimen must have been stable for 3 months prior to screening and until randomization
* For enrollment in the China extension, patients must have residence in mainland China, Hong Kong, or Taiwan and be of Chinese ancestry
* For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods

Exclusion Criteria

* Any evidence of a condition other than AD that may affect cognition
* History of schizophrenia, schizoaffective disorder, major depression, or bipolar disorder
* History or presence of clinically evident systemic vascular disease that in the opinion of the investigator has the potential to affect cognitive function
* History or presence of clinically evident cerebrovascular disease
* History or presence of posterior reversible encephalopathy syndrome
* History or presence of any stroke with clinical symptoms within the past 12 months, or documented history within the last 6 months of an acute event that is consistent with a transient ischemic attack
* History of severe, clinically significant CNS trauma
* History or presence of intracranial mass (e.g., glioma, meningioma) that could potentially impair cognition
* Presence of infections that affect brain function or history of infections that resulted in neurologic sequelae
* History or presence of systemic autoimmune disorders that potentially cause progressive neurologic disease with associated cognitive deficits
* At risk for suicide in the opinion of the investigator
* Alcohol and/or substance abuse or dependants in past 2 years
* Relevant brain hemorrhage, bleeding disorder and cerebrovascular abnormalities
* Any contraindications to brain MRI
* Unstable or clinically significant cardiovascular, kidney or liver disease
* Uncontrolled hypertension
* Unstable or clinically significant cardiovascular disease
* Abnormal thyroid function
* Patients with evidence of folic acid deficiency

Exclusion for Open-Label Extension (OLE):

* Discontinued from study treatment during the double-blind treatment period
* Received any other investigational medication during the double-blind treatment period or after the end of double-blind treatment
* Participation in the OLE deemed inappropriate by the investigator
* Presence of ARIA-E findings at the Week 116 MRI scan
Minimum Eligible Age

50 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hoffmann-La Roche

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Clinical Trials

Role: STUDY_DIRECTOR

Hoffmann-La Roche

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Center for Neurosciences

Tucson, Arizona, United States

Site Status

Global Clinical Trials; Irvine, CA

Irvine, California, United States

Site Status

Sutter Medical Group, Neurology

Sacramento, California, United States

Site Status

Syrentis Clinical Research

Santa Ana, California, United States

Site Status

California Neuroscience Research Medical Group, Inc

Sherman Oaks, California, United States

Site Status

Research Center for Clinical Studies, Inc.

Norwalk, Connecticut, United States

Site Status

JEM Research LLC

Atlantis, Florida, United States

Site Status

Bradenton Research Center

Bradenton, Florida, United States

Site Status

Brain Matters Research, Inc.

Delray Beach, Florida, United States

Site Status

Alzheimer?s Research and Treatment Center

Wellington, Florida, United States

Site Status

Columbus Memory Center

Columbus, Georgia, United States

Site Status

Center for Advanced Research & Education

Gainesville, Georgia, United States

Site Status

Southern Illinois University, School of Medicine

Springfield, Illinois, United States

Site Status

Fort Wayne Neurological Center

Fort Wayne, Indiana, United States

Site Status

Via Christi Research

Wichita, Kansas, United States

Site Status

Precise Research Centers

Flowood, Mississippi, United States

Site Status

University of Mississippi Medical Center

Jackson, Mississippi, United States

Site Status

Advanced Memory Research Institute of NJ

Toms River, New Jersey, United States

Site Status

Neurological Associates of Long Island, PC

Lake Success, New York, United States

Site Status

Columbia University Medical Center

New York, New York, United States

Site Status

Ohio State University; College of Medicine

Columbus, Ohio, United States

Site Status

Abington Neurological Associates

Abington, Pennsylvania, United States

Site Status

The Clinical Trial Center, LLC

Jenkintown, Pennsylvania, United States

Site Status

Drexel University; College of Medicine

Philadelphia, Pennsylvania, United States

Site Status

Coastal Neurology

Port Royal, South Carolina, United States

Site Status

Senior Adults Specialty Research

Austin, Texas, United States

Site Status

Neurology Consultants of Dallas; Research Department

Dallas, Texas, United States

Site Status

Wasatch Clinical Research, LLC

Salt Lake City, Utah, United States

Site Status

University of Virginia

Charlottesville, Virginia, United States

Site Status

Sentara Neurology Specialists

Norfolk, Virginia, United States

Site Status

Neurological Associates, Inc.

Richmond, Virginia, United States

Site Status

National Clinical Research Inc.-Richmond

Richmond, Virginia, United States

Site Status

UW Wisconsin-Madison

Madison, Wisconsin, United States

Site Status

St Vincent's Hospital Sydney; Neurology

Darlinghurst, New South Wales, Australia

Site Status

Central Coast Neurosciences Research

Erina, New South Wales, Australia

Site Status

Southern Neurology

Kogarah, New South Wales, Australia

Site Status

The Queen Elizabeth Hospital; Neurology

Woodville, South Australia, Australia

Site Status

Heidelberg Repatriation Hospital; Medical and Cognitive Research Centre

Heidelberg West, Victoria, Australia

Site Status

Neuro Trials Victoria

Noble Park, Victoria, Australia

Site Status

Australian Alzheimer's Research Foundation

Nedlands, Western Australia, Australia

Site Status

Hospital Nossa Senhora das Graças; Setor de Pesquisa em Neurologia

Curitiba, Paraná, Brazil

Site Status

Instituto de Neurologia de Curitiba

Curitiba, Paraná, Brazil

Site Status

Clinica Clinilive ltda

Maringá, Paraná, Brazil

Site Status

Hospital das Clinicas - UFRGS

Porto Alegre, Rio Grande do Sul, Brazil

Site Status

Clínica Dr. Norton Sayeg LTDA - EPP

São Paulo, São Paulo, Brazil

Site Status

Hospital das Clinicas - FMUSP_X; Neurologia

São Paulo, São Paulo, Brazil

Site Status

Medical Arts Health Research Group

Penticton, British Columbia, Canada

Site Status

The Medical Arts Health Research Group - West Vancouver

Vancouver, British Columbia, Canada

Site Status

Parkwood Hospital; Geriatric Medicine

London, Ontario, Canada

Site Status

Centre for Memory and Aging

Toronto, Ontario, Canada

Site Status

Sunnybrook Health Sciences Centre

Toronto, Ontario, Canada

Site Status

St. Michael'S Hospital

Toronto, Ontario, Canada

Site Status

Baycrest Health Sciences

Toronto, Ontario, Canada

Site Status

Devonshire Clinical Research

Woodstock, Ontario, Canada

Site Status

Center for Diagnosis and Research on Alzheimer's disease

Greenfield Park, Quebec, Canada

Site Status

Q & T Research Sherbrooke

Sherbrooke, Quebec, Canada

Site Status

Alpha Recherche Clinique

Québec, , Canada

Site Status

China-Japan Friendship Hospital

Beijing, , China

Site Status

Beijing Anding Hospital, Capital Medical University

Beijing, , China

Site Status

Beijing Tian Tan Hospital,Capital Medical University

Beijing, , China

Site Status

West China Hospital, Sichuan University

Chengdu, , China

Site Status

The First Affiliated Hospital, Chongqing Medical University

Chongqing, , China

Site Status

Fujian Medical University Union Hospital

Fuzhou, , China

Site Status

Sun Yat-sen Memorial Hospital; Neurology

Guangzhou, , China

Site Status

Guangdong Provincial People's Hospital; Breast

Guangzhou, , China

Site Status

Guangzhou First Municipal People's Hospital

Guangzhou, , China

Site Status

The Second Affiliated Hospital, Zhejiang University

Hangzhou, , China

Site Status

Sir Run Run Shaw Hospital

Hangzhou, , China

Site Status

Anhui Provincial Hospital

Hefei, , China

Site Status

The First Affiliated Hospital of Anhui Medical University

Hefei, , China

Site Status

The Second Affiliated Hospital to Nanchang University

Nanchang, , China

Site Status

Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School

Nanjing, , China

Site Status

Zhongda Hospital Affiliated to Southeast University

Nanjing, , China

Site Status

Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University)

Nanjing, , China

Site Status

Ruijin Hospital Shanghai Jiaotong University School of Medicine

Shanghai, , China

Site Status

Shanghai Mental Health Center

Shanghai, , China

Site Status

Huashan Hospital Affiliated to Fudan University

Shanghai, , China

Site Status

Shanghai First People's Hospital

Shanghai, , China

Site Status

Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Shanghai, , China

Site Status

Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Shanghai, , China

Site Status

The University of Hong Kong-Shenzhen Hospital; Local Ethic Committee

Shenzhen, , China

Site Status

Tianjin Medical University General Hospital

Tianjin, , China

Site Status

The First Affiliated Hospital of Wenzhou Medical College

Wenzhou, , China

Site Status

Northern Jangsu People's Hospital

Yangzhou, , China

Site Status

Henan Provincial People's Hospital

Zhengzhou, , China

Site Status

CHU Amiens Hopital Sud; Neurologie

Amiens Cedex1, , France

Site Status

Hôpital Avicenne; Centre de Recherche Clinique

Bobigny, , France

Site Status

Groupement Hospitalier Est - Hôpital Neurologique; Neurologie A (U502)

Bron, , France

Site Status

CHU de la Timone - Hopital d Adultes; Service de Neurologie

Marseille, , France

Site Status

Hôpital Lariboisière

Paris, , France

Site Status

CHU Poitiers - Hopital La Miletrie

Poitiers, , France

Site Status

CHU Strasbourg Hôpital Hautepierre

Strasbourg, , France

Site Status

Gerontopole; Centre de Recherche clinique

Toulouse, , France

Site Status

Hopital des Charpennes

Villeurbanne, , France

Site Status

Ambulates Gesundheitszentrum der Charité GmbH; MVZ Neurologie Campus Benjamin Franklin

Berlin, , Germany

Site Status

ECRC Experimental and Clinical Research Center, Charité Campus Berlin Buch, Memory Clinic

Berlin, , Germany

Site Status

St. Josef-Hospital, Klinik für Neurologie

Bochum, , Germany

Site Status

Universitätsklinikum Köln; Klinik und Poliklinik für Psychiatrie und Psychotherapie

Cologne, , Germany

Site Status

PANAKEIA - Arzneimittelforschung Leipzig GmbH

Leipzig, , Germany

Site Status

Universitätsmedizin derJohannes Gutenberg-Universität Mainz;Klinik für Psychiatrie und Psychotherapi

Mainz, , Germany

Site Status

Klinikum rechts der Isar der TU München; Klinik für Psychiatrie und Psychotherapie

München, , Germany

Site Status

Universitätsklinikum Münster; Klinik und Poliklinik für Neurologie

Münster, , Germany

Site Status

Universitätsklinikum Rostock Zentrum für Nervenheilkunde

Rostock, , Germany

Site Status

Universitätsklinikum Ulm; Klinik für Neurologie

Ulm, , Germany

Site Status

Studienzentrum Nordwest Dr med Joachim Springub Herr Wolfgang Schwarz

Westerstede, , Germany

Site Status

Forschungszentrum Ruhr

Witten, , Germany

Site Status

Semmelweis University; Department of Neurology

Budapest, , Hungary

Site Status

Nuovo Ospedale Civile S. Agostino-Estense; Clinica Neurologica ? Dipartimento di Neuroscienze

Modena, Emilia-Romagna, Italy

Site Status

Fondazione Santa Lucia IRCCS; Neurologia e Riabilitazione Neurologica

Rome, Lazio, Italy

Site Status

Umberto I Policlinico di Roma-Università di Roma La Sapienza

Rome, Lazio, Italy

Site Status

Ospedale San Giovanni Calibita Fatebenefratell;Neurologia

Rome, Lazio, Italy

Site Status

IRCCS ?Centro S. Giovanni di Dio? Fatebenefratelli -UO Alzheimer

Brescia, Lombardy, Italy

Site Status

IRCCS Ospedale San Raffaele; Centro Disturbi della Memoria

Milan, Lombardy, Italy

Site Status

ASST DI MONZA; Neurologia

Monza, Lombardy, Italy

Site Status

IRCCS Neuromed; Neurologia I-Centro studio e cura delle demenze e UVA

Pozzilli, Molise, Italy

Site Status

AO Città della Salute e della Scienza Osp.S.Giov.Battista Molinette; SC Geriatria

Turin, Piedmont, Italy

Site Status

Dipartimento delle Patologie Emergenti; Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone

Palermo, Sicily, Italy

Site Status

Medical Corporation Hakuyokai Kashiwado Hospital

Chiba, , Japan

Site Status

Inage Neurology and Memory Clinic

Chiba, , Japan

Site Status

Juntendo University Urayasu Hospital

Chiba, , Japan

Site Status

Southern Tohoku Medical Clinic

Fukushima, , Japan

Site Status

Yuai Clinic

Kanagawa, , Japan

Site Status

Shonan Kamakura General Hospital

Kanagawa, , Japan

Site Status

Mishima Hospital

Niigata, , Japan

Site Status

NHO Shizuoka Institute of Epilepsy and Neurological Disorders

Shizuoka, , Japan

Site Status

Shizuoka City Shimizu Hospital

Shizuoka, , Japan

Site Status

Jichiidai Station Brain Clinic

Tochigi, , Japan

Site Status

Yotsuya Medical Cube

Tokyo, , Japan

Site Status

Tokyo Medical and Dental University Hospital

Tokyo, , Japan

Site Status

Tokyo Medical University Hospital

Tokyo, , Japan

Site Status

Tokyo Metropolitan Geriatric Hospital

Tokyo, , Japan

Site Status

Nozomi Memory Clinic

Tokyo, , Japan

Site Status

National Center of Neurology and Psychiatry

Tokyo, , Japan

Site Status

P-One Clinic

Tokyo, , Japan

Site Status

Yamagata Tokusyukai Hospital

Yamagata, , Japan

Site Status

Vilnius University Hospital Santariskiu Clinics; Neurology

Vilnius, , Lithuania

Site Status

Hospital IV Alberto Sabogal Sologuren; Unidad de Investigacion

Bellavista, , Peru

Site Status

Clinica Internacional; Unidad De Investigacion

Lima, , Peru

Site Status

Hospital Nacional Dos de Mayo; Unidad de Investigacion de Neurologia

Lima, , Peru

Site Status

Hospital Nacional Cayetano Heredia; Servicio de Neurologia

San Martín de Porres, , Peru

Site Status

FSBHI Siberian Clinical Center of the Federal Medical and Biological Agency

Krasnoyarsk, Krasnoyarsk Krai, Russia

Site Status

University ?linic of headaches

Moscow, Moscow Oblast, Russia

Site Status

City Clin Hosp n.a. S.P.Botkin

Moscow, Moscow Oblast, Russia

Site Status

Central Clinical Hospital #2 N.A. Semashko OAO RJHD

Moskva, Moscow Oblast, Russia

Site Status

Russian Medical Military Academy n.a. S.M.Kirov; Neurology Department

Saint Petersburg, Sankt-Peterburg, Russia

Site Status

Vertebronevrologiya LLC

Kazan', Tatarstan Republic, Russia

Site Status

State autonomous institution of healthcare Inter-regional clinical and diagnostic center

Kazan', Tatarstan Republic, Russia

Site Status

City Clinical Hospital # 2 n.a. V.I. Razumovsky

Saratov, , Russia

Site Status

Nebbiolo Center for Clinical Trials

Tomsk, , Russia

Site Status

Hospital Universitari de Bellvitge; Servicio de Neurologia

L'Hospitalet de Llobregat, Barcelona, Spain

Site Status

Hospital General De Catalunya; Servicio de Neurologia

Sant Cugat del Vallès, Barcelona, Spain

Site Status

Hospital Universitario Marques de Valdecilla; Servicio de Neurología

Santander, Cantabria, Spain

Site Status

Hospital San Pedro; Servicio de Neurología

Logroño, La Rioja, Spain

Site Status

HM Universitario Puerta del Sur CINAC (C.Integ.Neuroc);; Servicio de Psiquiatría

Móstoles, Madrid, Spain

Site Status

Hospital General Universitario de Albacete; Servicio de Neurología

Albacete, , Spain

Site Status

Hospital Vall d'Hebron; Servicio de Neurología

Barcelona, , Spain

Site Status

Hospital Clinic i Provincial; Servicio de Neurologia

Barcelona, , Spain

Site Status

Hospital de la Santa Creu i Sant Pau; Servicio de Neurologia

Barcelona, , Spain

Site Status

Hospital Universitario Reina Sofia; Servicio de Neurologia

Córdoba, , Spain

Site Status

Hospital Ramon y Cajal; Servicio de Neurologia

Madrid, , Spain

Site Status

Hospital Ruber Internacional; Servicio de Neurología

Madrid, , Spain

Site Status

Hospital Universitario 12 de Octubre; Servicio de Neurologia

Madrid, , Spain

Site Status

Complejo Asistencial Universitario de Salamanca; Servicio de Psiquiatría

Salamanca, , Spain

Site Status

Hospital Virgen del Rocío; Servicio de Neurología

Seville, , Spain

Site Status

Hospital Universitario Dr. Peset; Servicio de Neurologia

Valencia, , Spain

Site Status

Servicio de Neurología Hospital Viamed Montecanal.

Zaragoza, , Spain

Site Status

Changhua Christian Hospital; Neurology

Changhua County, , Taiwan

Site Status

Kaohsiung Medical University Hospital; Neurology

Kaohsiung City, , Taiwan

Site Status

Chang Gung Memorial Foundation - Kaohsiung - Neurology

Niaosong Dist., , Taiwan

Site Status

China Medical University Hospital; Neurology

North Dist., , Taiwan

Site Status

National Taiwan University Hospital; Neurology

Taipei, , Taiwan

Site Status

Chang Gung Memorial Foundation - Linkou - Neurology

Taoyuan District, , Taiwan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Brazil Canada China France Germany Hungary Italy Japan Lithuania Peru Russia Spain Taiwan

References

Explore related publications, articles, or registry entries linked to this study.

Chandler JM, Lansdall CJ, Ye W, McDougall F, Belger M, Toth B, Mi X, Sink KM, Atkins AS. The Alzheimer's Disease Cooperative Study - Activities of Daily Living dependence score: revision and validation of an algorithm evaluating patient dependence across the spectrum of AD severity. J Prev Alzheimers Dis. 2025 Sep;12(8):100261. doi: 10.1016/j.tjpad.2025.100261. Epub 2025 Jul 1.

Reference Type DERIVED
PMID: 40603145 (View on PubMed)

Asada T, Thanasopoulou A, Delmar P, Wojtowicz J, Smith J, Yoshiyama Y, Yokoi K, Watanabe C, Isozaki M, Ozaki R, Ishida T, Tatsuda H, Tamaoka A. Japanese participant data from three gantenerumab trials in early Alzheimer's disease. Alzheimers Dement. 2025 Apr;21(4):e70192. doi: 10.1002/alz.70192.

Reference Type DERIVED
PMID: 40302041 (View on PubMed)

Bittner T, Tonietto M, Klein G, Belusov A, Illiano V, Voyle N, Delmar P, Scelsi MA, Gobbi S, Silvestri E, Barakovic M, Napolitano A, Galli C, Abaei M, Blennow K, Barkhof F. Biomarker treatment effects in two phase 3 trials of gantenerumab. Alzheimers Dement. 2025 Feb;21(2):e14414. doi: 10.1002/alz.14414. Epub 2025 Jan 30.

Reference Type DERIVED
PMID: 39887500 (View on PubMed)

Salloway S, Wojtowicz J, Voyle N, Lane CA, Klein G, Lyons M, Rossomanno S, Mazzo F, Bullain S, Barkhof F, Bittner T, Schneider A, Grundman M, Aldea R, Boada M, Smith J, Doody R. Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease. JAMA Neurol. 2025 Jan 1;82(1):19-29. doi: 10.1001/jamaneurol.2024.3937.

Reference Type DERIVED
PMID: 39556389 (View on PubMed)

Bateman RJ, Smith J, Donohue MC, Delmar P, Abbas R, Salloway S, Wojtowicz J, Blennow K, Bittner T, Black SE, Klein G, Boada M, Grimmer T, Tamaoka A, Perry RJ, Turner RS, Watson D, Woodward M, Thanasopoulou A, Lane C, Baudler M, Fox NC, Cummings JL, Fontoura P, Doody RS; GRADUATE I and II Investigators and the Gantenerumab Study Group. Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease. N Engl J Med. 2023 Nov 16;389(20):1862-1876. doi: 10.1056/NEJMoa2304430.

Reference Type DERIVED
PMID: 37966285 (View on PubMed)

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2017-001364-38

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

WN29922

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.